KLK11 Polyclonal Antibody, Cy3 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3799R-Cy3 |
| Product Name | KLK11 Polyclonal Antibody, Cy3 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human KLK11 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 11012 |
| Subcellular location | Cytoplasm, Secreted |
| Synonyms | Hippostasin; hK11; KLK 11; KLK-11; kallikrein 11; Kallikrein 11 isoform 1 preproprotein; Kallikrein 11 isoform 2 precursor; Kallikrein 11 precursor; kallikrein related peptidase 11; KLK 11; KLK11; Protease serine 20 trypsin like; Protease serine trypsin like; PRSS20; Serine protease 20; TLSP; Trypsin like protease; KLK11_HUMAN. |
| Background | Kallikrein 11 has two alternative splicing isoforms, known as the brain type and prostate type. Elevated serum levels of hK11 have been found in 70% of women with ovarian cancer and in 60% of men with prostate cancer. Analysis of this biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |